Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–80.
2. Soleimani B, Murray K, Hunt D. Established and emerging immunological complications of biological therapeutics in multiple sclerosis. Drug Saf. 2019;42(8):941–56.
3. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–87.
4. Hauser SL, Belachew S, Kappos L. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med. 2017;376(17):1694.
5. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73(5):372–7.